Danilo Antonio Baltieri1, Arthur Guerra de Andrade. 1. Program for Prevention of the Interdisciplinary Study Group of Alcohol and Drugs of the Psychiatric Institute of the Clinical Hospital of the Medical School of the University of São Paulo. São Paulo, SP, Brazil.
Abstract
OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION:Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS:Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION:Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.
Authors: Bruno Scherrer; Julien Guiraud; Giovanni Addolorato; Henri-Jean Aubin; Andrea de Bejczy; Amine Benyamina; Wim van den Brink; Fabio Caputo; Maurice Dematteis; Anna E Goudriaan; Antoni Gual; Falk Kiefer; Lorenzo Leggio; Otto-Michael Lesch; Icro Maremmani; David J Nutt; François Paille; Pascal Perney; Roch Poulnais; Quentin Raffaillac; Jürgen Rehm; Benjamin Rolland; Nicolas Simon; Bo Söderpalm; Wolfgang H Sommer; Henriette Walter; Rainer Spanagel Journal: Alcohol Clin Exp Res Date: 2021-08-21 Impact factor: 3.928
Authors: Catherine A Staton; João Ricardo Nickenig Vissoci; Deena El-Gabri; Konyinsope Adewumi; Tessa Concepcion; Shannon A Elliott; Daniel R Evans; Sophie W Galson; Charles T Pate; Lindy M Reynolds; Nadine A Sanchez; Alexandra E Sutton; Charlotte Yuan; Alena Pauley; Luciano Andrade; Megan Von Isenberg; Jinny J Ye; Charles J Gerardo Journal: PLoS Med Date: 2022-04-12 Impact factor: 11.069